Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Korsana Biosciences, Inc. (KRSA)

Korsana completes Cyclerion merger and $380 million private placement

Mixed Impact 5 of 5 m&a Written later

Korsana Biosciences completed its merger with Cyclerion Therapeutics on September 8, 2026, and the combined company is set to trade on Nasdaq under the ticker KRSA starting September 9. The closing included a $380 million private placement and a 1-for-7 reverse split of Cyclerion common stock, leaving about 55.1 million shares and share equivalents outstanding, excluding equity awards. The company expects pro-forma cash of about $475 million to fund operations into 2029, but it reported a $30.9 million net loss for the six months ended June 30, 2026.

Key points

  • Merger closed September 8, 2026; shares begin trading on Nasdaq as KRSA on September 9, 2026
  • $380 million gross proceeds from a private placement led by Fairmount and Venrock Healthcare Capital Partners
  • About 55.1 million shares and share equivalents outstanding after closing, excluding equity awards
  • Pro-forma cash of about $475 million, expected to fund operations into 2029; net loss of $30.9 million for the six months ended June 30, 2026

The filing

CompanyKorsana Biosciences, Inc. (KRSA)
Form8-K, current report
Filed with the SECSep 11, 2026, 4:25 PM ET
Accession number0001193125-26-389318

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.02 Results of Operations3.02 Unregistered Equity Sale3.03 Change to Shareholder Rights5.01 Change in Control5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.05 Code of Ethics Change5.067.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.